In Brief: Oncologic Drugs Advisory Committee
Oncologic Drugs Advisory Committee: Janssen's Liazal (liarozole fumarate, NDA 27-094) will be reviewed the morning of June 24 for treatment of advanced prostate cancer. On June 23, committee will consider Ilex' Zyrkamine (mitoguazone, NDA 20-709) for treatment of AIDS-related non-Hodgkin's lymphoma and Bristol-Myers Squibb's Taxol (paclitaxel, NDA 20-262) for second-line treatment of AIDS-related Kaposi's sarcoma. The meeting will take place at the Holiday Inn-Bethesda, Md. beginning 8:30 a.m. on June 23 and 9 a.m. June 24...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth